Income statement
GBP
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -84K | -102K | -195K | -260K |
| Operating Income | -8M | -10M | -20M | -58M | -18M |
| EBITDA | -8M | -10M | -20M | -58M | -17M |
| Net Income | -7M | -8M | -18M | -49M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Synairgen plc (SYGGF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +19.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +19.1%, free cash flow +4.0% with operating margin 0.0% and ROIC -70.8%. Stock Foundry combines SYGGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYGGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYGGF Max Drawdown
-97.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYGGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$13.9M
+71.4% YoY
Free Cash Flow
-$23.9M
+41.8% YoY
Revenue Growth
+0.0%
EPS Growth
+19.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
GBP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -84K | -102K | -195K | -260K |
| Operating Income | -8M | -10M | -20M | -58M | -18M |
| EBITDA | -8M | -10M | -20M | -58M | -17M |
| Net Income | -7M | -8M | -18M | -49M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 11M | 16M | 34M | 75M |
| Total Assets | 8M | 14M | 24M | 45M | 89M |
| Total Liabilities | 2M | 2M | 3M | 8M | 3M |
| Shareholder Equity | 6M | 13M | 20M | 37M | 85M |
| Total Debt | 0 | 0 | 0 | 0 | 128K |
| Net Debt | -5M | -11M | -16M | -34M | -75M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
+41.9% YoY
Capital Expenditures
76K
-130.3% YoY
Free Cash Flow
24M
+41.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.